Storage and beyond-use dates depend on the exact formulation. This guide identifies whether label-based instructions exist and does not invent universal shelf lives.
| Name | Exact formulation | Storage source | Evidence |
|---|---|---|---|
| Adamax | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | No compound-specific human clinical evidence located |
| AOD-9604 | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Human development did not establish weight-loss efficacy |
| BPC-157 | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Preclinical studies and small human reports |
| Cerebrolysin | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Clinical trials; uncertain benefit and a possible serious-adverse-event signal |
| CJC-1295 and modified GRF | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Early human hormone studies; formulation matters |
| Dihexa | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Preclinical evidence undermined by a foundational retraction |
| DSIP | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Old, small and inconsistent human literature |
| Epithalon | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Cell-line and limited historical research; no injected anti-aging outcome evidence |
| GHK-Cu | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Limited topical human studies; injection benefits unestablished |
| IGF-1 LR3 | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Preclinical evidence |
| Ipamorelin | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Limited human studies; routine benefit unestablished |
| KLOW blend | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | No blend-specific clinical evidence |
| KPV | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Preclinical evidence only for claimed uses |
| MOTS-c | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Preclinical treatment evidence |
| Melanotan II | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Small human studies; serious safety concerns |
| NAD+ | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Biochemical rationale; clinical wellness claims unestablished |
| PT-141 | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Approved for a defined HSDD population |
| Retatrutide | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Phase 3 sponsor topline; investigational and not FDA-approved |
| Selank | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Small active-comparator study; no FDA approval |
| Semaglutide | Ozempic, Wegovy, Wegovy HD and Rybelsus in their labeled indications | Use the current approved label and dispensing instructions. | FDA-approved medicines; instructions are product and indication specific |
| Semax | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Limited regional clinical literature; U.S. uses unapproved |
| Sermorelin | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Historical diagnostic/pediatric product; claimed adult uses unestablished |
| Elamipretide | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | FDA accelerated approval for a narrow indication |
| Survodutide | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Published Phase 3 obesity trial; still investigational |
| TB-500 | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Human treatment evidence not established |
| Tesamorelin | No FDA-approved formulation identified | No validated universal storage period; do not infer one from the CDC multidose-vial convention. | Approved for HIV-associated lipodystrophy |
| Tirzepatide | Mounjaro and Zepbound in their labeled indications | Use the current approved label and dispensing instructions. | FDA-approved medicines with direct comparative trial evidence |
← Browse all profiles | Prescription arithmetic →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify